Compare Stocks: BCRX, APGE, PCVX, and CYTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.79	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
BCRX BioCryst Pharmaceuticals	$8.17 +0.6%	$9.26	$6.00 ▼ $11.22	$2.09B	0.55	4.89 million shs	6.14 million shs
CYTK Cytokinetics	$65.60 0.0%	$73.77	$54.30 ▼ $88.31	$8.16B	0.41	2.14 million shs	2.65 million shs
PCVX Vaxcyte	$56.48 +0.8%	$58.63	$39.87 ▼ $65.00	$8.40B	1.23	1.39 million shs	2.40 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	-0.01%	+1.63%	+242.99%
BCRX BioCryst Pharmaceuticals	-2.52%	-4.69%	-18.15%	-17.48%	+10.18%
CYTK Cytokinetics	-0.44%	-0.06%	-8.10%	-24.13%	+17.51%
PCVX Vaxcyte	-1.70%	-1.49%	-7.83%	-4.01%	+47.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.79	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
BCRX BioCryst Pharmaceuticals	$8.17 +0.6%	$9.26	$6.00 ▼ $11.22	$2.09B	0.55	4.89 million shs	6.14 million shs
CYTK Cytokinetics	$65.60 0.0%	$73.77	$54.30 ▼ $88.31	$8.16B	0.41	2.14 million shs	2.65 million shs
PCVX Vaxcyte	$56.48 +0.8%	$58.63	$39.87 ▼ $65.00	$8.40B	1.23	1.39 million shs	2.40 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	-0.01%	+1.63%	+242.99%
BCRX BioCryst Pharmaceuticals	-2.52%	-4.69%	-18.15%	-17.48%	+10.18%
CYTK Cytokinetics	-0.44%	-0.06%	-8.10%	-24.13%	+17.51%
PCVX Vaxcyte	-1.70%	-1.49%	-7.83%	-4.01%	+47.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.16	Hold	$126.77	-6.14% Downside
BCRX BioCryst Pharmaceuticals	2.50	Moderate Buy	$20.50	152.31% Upside
CYTK Cytokinetics	2.85	Moderate Buy	$106.00	62.86% Upside
PCVX Vaxcyte	2.63	Moderate Buy	$104.40	85.58% Upside

Current Analyst Ratings Breakdown

Latest BCRX, APGE, PCVX, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$12.00 ➝ $13.00
9/28/2026	PCVX Vaxcyte	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$133.00 ➝ $130.00
9/25/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/22/2026	BCRX BioCryst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Sell (D-)
9/11/2026	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$13.00 ➝ $11.00
9/8/2026	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/1/2026	CYTK Cytokinetics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight ➝ Buy
8/31/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00
8/27/2026	BCRX BioCryst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/14/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
BCRX BioCryst Pharmaceuticals	$874.84M	2.37	$1.21 per share	6.73	($0.57) per share	-14.25
CYTK Cytokinetics	$88.04M	91.99	N/A	N/A	($5.39) per share	-12.08
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	11.28	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)

Latest BCRX, APGE, PCVX, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
CYTK Cytokinetics	N/A	6.66	6.66
PCVX Vaxcyte	N/A	5.72	5.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BCRX BioCryst Pharmaceuticals	85.88%
CYTK Cytokinetics	N/A
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
BCRX BioCryst Pharmaceuticals	3.80%
CYTK Cytokinetics	2.60%
PCVX Vaxcyte	3.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
BCRX BioCryst Pharmaceuticals	435	255.54 million	245.83 million	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
PCVX Vaxcyte	507	148.80 million	143.89 million	Optionable

BCRX, APGE, PCVX, and CYTK Headlines

Recent News About These Companies

Vaxcyte (NASDAQ:PCVX) Stock: Insider Jim Wassil Sells 2,250 Shares

1 hour ago | marketbeat.com

Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says

September 28, 2026 | finance.yahoo.com

Vaxcyte (NASDAQ:PCVX) Stock Rating Reaffirmed as "Buy" by Needham & Company LLC

September 27, 2026 | americanbankingnews.com

Vaxcyte's (PCVX) "Buy" Rating Reaffirmed at Needham & Company LLC

September 25, 2026 | marketbeat.com

Vaxcyte, Inc. $PCVX Shares Acquired by Corient Private Wealth LP

September 24, 2026 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | americanbankingnews.com

Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Rating of "Moderate Buy" from Analysts

September 23, 2026 | marketbeat.com

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

September 22, 2026 | zacks.com

Vaxcyte stock gains 1.36 percent as shares close at USD 58.92

September 22, 2026 | ad-hoc-news.deA

Vaxcyte (PCVX) Dropped, So What Is Driving Attention Now?

September 21, 2026 | finance.yahoo.com

Bank of America Corp DE Invests $62.71 Million in Vaxcyte, Inc. $PCVX

September 20, 2026 | marketbeat.com

Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears

September 17, 2026 | finance.yahoo.com

Engineers Gate Manager LP Invests $1.91 Million in Vaxcyte, Inc. $PCVX

September 16, 2026 | marketbeat.com

California State Teachers Retirement System Acquires 4,733 Shares of Vaxcyte, Inc. $PCVX

September 15, 2026 | marketbeat.com

Insider Selling: Vaxcyte (NASDAQ:PCVX) EVP Sells $79,399.68 in Stock

September 10, 2026 | insidertrades.com

First Light Asset Management LLC Buys 203,373 Shares of Vaxcyte, Inc. $PCVX

September 10, 2026 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) EVP Sells $79,399.68 in Stock

September 9, 2026 | marketbeat.com

Jim Wassil Sells 1,381 Shares of Vaxcyte (NASDAQ:PCVX) Stock

September 9, 2026 | marketbeat.com

Vaxcyte Target of Unusually Large Options Trading (NASDAQ:PCVX)

September 8, 2026 | marketbeat.com

A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know

September 8, 2026 | fool.com

Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm

September 8, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, APGE, PCVX, and CYTK Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$135.07 0.00 (0.00%)

As of 09/4/2026

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.17 +0.05 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$8.09 -0.08 (-0.98%)

As of 05:49 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Cytokinetics NASDAQ:CYTK

$65.60 -0.02 (-0.03%)

Closing price 04:00 PM Eastern

Extended Trading

$64.98 -0.61 (-0.94%)

As of 05:07 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vaxcyte NASDAQ:PCVX

$56.48 +0.43 (+0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$56.48 0.00 (-0.01%)

As of 05:18 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCRX, APGE, PCVX, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCRX, APGE, PCVX, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCRX, APGE, PCVX, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, APGE, PCVX, and CYTK Company Descriptions

Apogee Therapeutics NASDAQ:APGE

BioCryst Pharmaceuticals NASDAQ:BCRX

Cytokinetics NASDAQ:CYTK

Vaxcyte NASDAQ:PCVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCRX, APGE, PCVX, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCRX, APGE, PCVX, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCRX, APGE, PCVX, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, APGE, PCVX, and CYTK Company Descriptions

Apogee Therapeutics NASDAQ:APGE

BioCryst Pharmaceuticals NASDAQ:BCRX

Cytokinetics NASDAQ:CYTK

Vaxcyte NASDAQ:PCVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools